Abstract

Gastroesophageal reflux disease is a common digestive disorder often associated with medication use. This study aimed to identify top medications strongly associated with gastroesophageal reflux disease through the Food and Drug Administration's adverse event reporting system. Food and Drug Administration's adverse event reporting system database was queried for adverse event reports related to gastroesophageal reflux disease from 2013 to 2022. Disproportionality analysis was conducted using the reporting odds ratio and proportional reporting ratio. To identify instances of gastroesophageal reflux disease, the medical dictionary for regulatory activities was utilized and the DrugBank database was used to determine the generic nomenclature of the drugs. A total of 5470 cases of gastroesophageal reflux disease reports were identified. Overall, there is a higher likelihood of drug-induced gastroesophageal reflux disease in females. Benicar, Fosamax, Enbrel, Benicar HCT and Prolia were the top 5 drugs associated with most cases of gastroesophageal reflux disease. According to the disproportionality analysis, Benicar and its combination medications ranked as the top three drugs with the strongest gastroesophageal reflux disease signals. By analyzing the Food and Drug Administration's adverse event reporting system database, we have listed medications with a strong gastroesophageal reflux disease signal. Our research indicated that angiotensin II receptor blockers, particularly Benicar (olmesartan), might be a category of drugs with underestimated susceptibility to gastroesophageal reflux disease risk.